课题基金 / 基金详情

Advancing drug-lead and chemical-probe discovery using weighted-ensemble simulations and biophysical validation

Advancing drug-lead and chemical-probe discovery using weighted-ensemble simulations and biophysical validation
使用加权集成模拟和生物物理验证推进先导药物和化学探针的发现
批准号:
10727033
负责人:
Jacob D Durrant
金额:
$6.91万
依托单位国家:
美国
项目类别:
财政年份:
2019
资助国家:
美国
项目状态:
已结题
起止时间:
2019-09-01 至 2024-06-30

项目摘要

项目成果

Jacob D Durrant的其他基金

相似基金

相关文献

中文摘要
翻译
项目总结
英文摘要
Project Summary This project will study La-related protein 1 (LARP1), a molecular switch that allows cells to rapidly increase protein synthesis. LARP1 stores and protects the mRNA molecules required to make ribosomal proteins. In response to pro-growth signals or cancer, the mammalian target of rapamycin complex 1 (mTORC1) causes LARP1 to release its bound mRNAs. Ribosome production surges, leading to rapid increases in protein synthesis generally. Our strong preliminary data has led us to two central hypotheses. First, we hypothesize that LARP1- binding molecules (ligands) will interfere with the LARP1 mRNA-storage mechanism, thereby reducing protein synthesis. Second, we hypothesize that better understanding the flexibility of molecule-binding protein pockets—including LARP1 pockets—will improve rational ligand design. We will test these hypotheses in two aims. Aim 1 will create a new pocket-centric method for simulating proteins, called SubPEx. We will show that SubPEx can effectively reveal the flexibility of two well-characterized dynamic pockets (from TEM-1 b- lactamase and influenza neuraminidase). Aim 2 will use SubPEx, virtual screening, and biophysical experiments to identify new ligands that bind flexible LARP1 pockets. This work is significant in several ways. LARP1 ligands will serve as basic-science tools (chemical probes) to advance our understanding of LARP1 biology. Additionally, cancer requires extensive protein synthesis, so molecules that disrupt mTORC1-LARP1 signaling will serve as leads that will further the development of new therapies. Most mTORC1-pathway inhibitors bind mTOR itself. They are subject to resistance mutations and/or incomplete inhibition. LARP1 inhibition will provide a unique and innovative pharmacological approach. SubPEx itself will also be impactful. Many protein drug targets have highly flexible binding pockets, and successful structure-based drug design must account for that flexibility. Unlike other methods for exploring protein flexibility, SubPEx will focus computational effort on the binding pocket itself. Its permissive, open- source license will encourage adoption. We expect that many in the broader community will also use SubPEx to design ligands that bind their own disease-relevant proteins of interest.
期刊论文(13)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1021/acs.jcim.1c00103
发表时间: 2021-06-28
期刊: Journal of chemical information and modeling
影响因子: 5.6
作者: [Green H, Durrant JD]
通讯作者: Durrant JD
DOI: 10.1039/d1sc00163a
发表时间: 2021-05-08
期刊: Chemical science
影响因子: 8.4
作者: [Green H, Koes DR, Durrant JD]
通讯作者: Durrant JD
DOI: 10.1186/s13321-020-00471-2
发表时间: 2020-11-11
期刊: Journal of cheminformatics
影响因子: 8.6
作者: [Ha EJ, Lwin CT, Durrant JD]
通讯作者: Durrant JD
DOI: 10.1093/bioinformatics/btaa579
发表时间: 2020-08-15
期刊: Bioinformatics (Oxford, England)
影响因子: --
作者: [Kochnev Y, Hellemann E, Cassidy KC, Durrant JD]
通讯作者: Durrant JD
共 9 条
    Advancing drug-lead and chemical-probe discovery using weighted-ensemble simulations and biophysical validation
    Advancing drug-lead and chemical-probe discovery using weighted-ensemble simulations and biophysical validation
    Advancing drug-lead and chemical-probe discovery using weighted-ensemble simulations and biophysical validation
    Advancing drug-lead and chemical-probe discovery using weighted-ensemble simulations and biophysical validation
    海外基金